JYNT
The Joint Corp
NASDAQ: JYNT · HEALTHCARE · MEDICAL CARE FACILITIES
$8.68
+0.73% today
Updated 2026-06-05
Market cap
$118.18M
P/E ratio
92.11
P/S ratio
2.09x
EPS (TTM)
$0.09
Dividend yield
—
52W range
$8 – $13
Volume
0.1M
WallStSmart proprietary scores
47
out of 100
Grade: C
Sell
Investment rating
6.0
Growth
B6.5
Quality
B5.5
Profitability
C+3.0
Valuation
D6/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$10.00
+15.21%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 20.94% — strong efficiency
+ Revenue growth 13.30% QoQ
+ Debt/equity 0.13x — low leverage
Risks
- Altman Z 0.86 — distress zone
- Negative free cash flow $-1.71M
- P/E 92.11x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $101.25M | $46.98M | $52.16M | $54.90M | $56.64M |
| Net income | $626705.00 | $-9.75M | $-5.80M | $2.91M | $1.30M |
| EPS | — | — | — | — | $0.09 |
| Free cash flow | $2.31M | $9.68M | $8.23M | $334724.00 | $-1.71M |
| Profit margin | 0.62% | -20.76% | -11.11% | 5.30% | 5.72% |
Peer comparison
Smart narrative
The Joint Corp trades at $8.68. representing a P/E of 92.11x trailing earnings. Our Smart Value Score of 47/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 0.86, it sits in the distress. TTM revenue stands at $56.64M. with profit margins at 5.72%.
Frequently asked questions
What is The Joint Corp's stock price?
The Joint Corp (JYNT) trades at $8.68, on a P/E of 92.1x and a P/S of 2.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is The Joint Corp overvalued?
The Joint Corp carries a Smart Value Score of 47/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of The Joint Corp (JYNT)?
The 12-month analyst consensus target is $10.00, about 15.2% above the current $8.68. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is The Joint Corp's revenue?
The Joint Corp's trailing twelve-month revenue is $56.64M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
The Joint Corp's Altman Z-Score is 0.86, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL CARE FACILITIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.09x
ROE20.94%
Beta1.10
50D MA$8.76
200D MA$9.02
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—